Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05147805 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT05147805 is a Phase 2 study that has completed, run by Insmed Incorporated. The registered enrollment target is 102 participants.
The verdict
NCT05147805, a Phase 2 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
Interventions
- DRUG Placebo
- DRUG Treprostinil Palmitil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2025-03-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05147805
The ClinicalTrials.gov registry entry for NCT05147805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05147805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05147805 about?
NCT05147805 is a clinical study titled "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension". The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
What is the current status of trial NCT05147805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2022-08-24. Estimated completion is 2025-03-27.
What interventions are being tested in trial NCT05147805?
The interventions under investigation include: Placebo (DRUG), Treprostinil Palmitil (DRUG).
Who is sponsoring clinical trial NCT05147805?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.